FDA Alzheimer's Drug OK Opens Door To Medicare Coverage
The U.S. Food and Drug Administration handed full approval to Eisai and Biogen's Alzheimer's treatment Leqembi on Thursday following a study that verified the drug's ability to slow cognitive decline in the...To view the full article, register now.
Already a subscriber? Click here to view full article